Clinical applications - Graft engineering - Background

Background

Hematopoietic stem cell transplantation (HSCT) is a well-founded therapeutic option for the treatment of a variety of hematologic malignancies and a number of non-malignant diseases.41 Different clinical strategies are being evaluated to engineer stem cell grafts for different purposes based on Miltenyi Biotec technologies and clinical grade antibodies for different epitopes.

 

Clinical research in graft manipulation include the
  • depletion of T and B cells in order to prevent severe graft-versus-host disease (GvHD) and post-transplant lymphoproliferative diseases (PTLPD) in allogeneic transplantation,
  • depletion of autoreactive T and B cells in autologous transplantation for autoimmune diseases,
  • removal of contaminating tumor cells from a graft in autologous transplantation.

The CliniMACS® System allows either
  • the passive depletion of T and B cells by CD34+ or CD133+ cell enrichment, or
  • the direct depletion of T and B cells by combined CD3/CD19 or TCRα/β/CD19 depletion.

Customer login

Go

Forgot password?
Register for account

0 Shopping cart

Contact

Miltenyi Biotec Inc.
Phone: +1 800 FOR MACS
Fax:+1 877 591 1060
macs@miltenyibiotec.com
Contact overview

Product finder

Antibody panel builder

Toolbox

Loading...
References

References

Your opinion matters

Your opinion matters

Change country

Please select your country to continue